Oral Contraceptive Use, Colorectal Cancer: Possible Relationships
the Cancer Therapy Advisor take:
A potential association was recognized between oral contraceptive (OC) use by younger women for long durations and possible protection for colorectal cancer, according to an article published online in the journal Cancer Epidemiology, Biomarkers & Prevention.
The researchers analyzed and categorized OC use every 2 years from 1976 to 2010 using data of 88,691 participants in the Nurses’ Health Study I (NHSI) and of 93,080 participants in the Nurses’ Health Study II (NHSII).
The categories that were established included ever use, duration of use, and time since last use. All incident colorectal cancer cases from NHSI and NHSII through 2010 were included in the analysis (age at diagnosis = 36–88, N = 1,764 and age at diagnosis = 33–64, N = 206, respectively).
Results showed ever OC use was not related to colorectal cancer incidence in NHSI nor in NHSII [1.01 (0.91, 1.12) and 1.03 (0.69, 1.53), respectively.]
The longer duration (5+ years) OC use cohort in NHSII was inversely associated with the risk of colon cancers (Ptrend = 0.02) compared to never-users—although endpoints were limited.
Little evidence was found to support an association between OC use and protection against colorectal cancer; however, the potential association between longer duration OC use by younger women warrants further study.
A potential association was recognized between oral contraceptive use by younger women and protection for colorectal cancer.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Arrival of CAR-T Immunotherapy Raise Hopes for Treatment and Anxieties About Costs
- St John's Wort and Cancer
- Osimertinib Granted Breakthrough Therapy Designation as First-line Treatment for EGFR-positive NSCLC
- Radiation Therapy Increases 5-year Rate of Cardiac Events in Small-cell Lung Cancer
- FDA Grants Priority Review to Afatinib for Uncommon EGFR-positive NSCLC
- NSCLC: Researchers Identify Socioeconomic Factors Linked to Overall Survival
- Savolitinib Plus Gefitinib May Be Effective in EGFR-Mutant, MET-amplified NSCLC
- Maintenance Pazopanib Provides PFS, not OS, Benefit in Small-cell Lung Cancer
- Pembrolizumab Plus Pemetrexed, Carboplatin Prolongs Survival in NSCLC
- Repeat T790M Testing Recommended for TKI-resistant Patients With NSCLC